CN116635032A - 用于治疗眼部病症的化合物和方法 - Google Patents
用于治疗眼部病症的化合物和方法 Download PDFInfo
- Publication number
- CN116635032A CN116635032A CN202180086872.2A CN202180086872A CN116635032A CN 116635032 A CN116635032 A CN 116635032A CN 202180086872 A CN202180086872 A CN 202180086872A CN 116635032 A CN116635032 A CN 116635032A
- Authority
- CN
- China
- Prior art keywords
- substituted
- radical
- alkyl
- compound
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063094808P | 2020-10-21 | 2020-10-21 | |
| US63/094,808 | 2020-10-21 | ||
| PCT/IB2021/000708 WO2022084739A1 (en) | 2020-10-21 | 2021-10-20 | Compounds and methods for the treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116635032A true CN116635032A (zh) | 2023-08-22 |
Family
ID=81290138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180086872.2A Pending CN116635032A (zh) | 2020-10-21 | 2021-10-20 | 用于治疗眼部病症的化合物和方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230399317A1 (https=) |
| EP (1) | EP4232034A4 (https=) |
| JP (1) | JP2023546452A (https=) |
| KR (1) | KR20230110516A (https=) |
| CN (1) | CN116635032A (https=) |
| AU (1) | AU2021365530A1 (https=) |
| CA (1) | CA3196146A1 (https=) |
| IL (1) | IL302174A (https=) |
| MX (1) | MX2023004538A (https=) |
| WO (1) | WO2022084739A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024100454A2 (en) * | 2022-11-11 | 2024-05-16 | Azura Ophthalmics Ltd. | Composition and methods for improving signs and symptoms of ocular disorders |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102065694A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂 |
| CN104955453A (zh) * | 2012-12-19 | 2015-09-30 | 原生质生物科学股份有限公司 | Lfa-1抑制剂制剂 |
| US9463201B2 (en) * | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| CN109328061A (zh) * | 2016-04-19 | 2019-02-12 | 阿祖拉眼科有限公司 | 用于治疗角化过度症的组合物 |
| WO2020212755A1 (en) * | 2019-04-18 | 2020-10-22 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CN114025759A (zh) * | 2019-04-18 | 2022-02-08 | 阿祖拉眼科有限公司 | 用于治疗眼病的化合物和方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2830024T3 (es) * | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
| US10688122B2 (en) * | 2015-09-28 | 2020-06-23 | Azura Ophthalmics Ltd. | Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion |
| EP3600272A4 (en) * | 2017-03-29 | 2021-01-13 | Azura Ophthalmics Ltd. | MEANS OF INCREASING LIPID SECRETION OF THE MEIBOMAN GLAND |
| WO2018212846A1 (en) * | 2017-05-19 | 2018-11-22 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| US20180333357A1 (en) * | 2017-05-19 | 2018-11-22 | Ocugen, Inc. | Nanoemulsions with anti-inflammatory activity |
| WO2019053607A1 (en) * | 2017-09-18 | 2019-03-21 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING LIFITEGRAST |
| US11001574B2 (en) * | 2017-11-17 | 2021-05-11 | Medichem S.A. | Process to obtain a tetrahydroisoquinoline derivative |
-
2021
- 2021-10-20 EP EP21882227.8A patent/EP4232034A4/en active Pending
- 2021-10-20 KR KR1020237016473A patent/KR20230110516A/ko active Pending
- 2021-10-20 IL IL302174A patent/IL302174A/en unknown
- 2021-10-20 WO PCT/IB2021/000708 patent/WO2022084739A1/en not_active Ceased
- 2021-10-20 JP JP2023524274A patent/JP2023546452A/ja active Pending
- 2021-10-20 AU AU2021365530A patent/AU2021365530A1/en not_active Abandoned
- 2021-10-20 MX MX2023004538A patent/MX2023004538A/es unknown
- 2021-10-20 CA CA3196146A patent/CA3196146A1/en active Pending
- 2021-10-20 US US18/033,055 patent/US20230399317A1/en active Pending
- 2021-10-20 CN CN202180086872.2A patent/CN116635032A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102065694A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂 |
| CN104955453A (zh) * | 2012-12-19 | 2015-09-30 | 原生质生物科学股份有限公司 | Lfa-1抑制剂制剂 |
| US9463201B2 (en) * | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| CN109328061A (zh) * | 2016-04-19 | 2019-02-12 | 阿祖拉眼科有限公司 | 用于治疗角化过度症的组合物 |
| WO2020212755A1 (en) * | 2019-04-18 | 2020-10-22 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CN114025759A (zh) * | 2019-04-18 | 2022-02-08 | 阿祖拉眼科有限公司 | 用于治疗眼病的化合物和方法 |
Non-Patent Citations (1)
| Title |
|---|
| 崛口博等: "公害与毒物、危险物 有机篇", 31 October 1978, 石油化学工业出版社, pages: 553 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023004538A (es) | 2023-06-19 |
| KR20230110516A (ko) | 2023-07-24 |
| AU2021365530A1 (en) | 2023-06-15 |
| EP4232034A4 (en) | 2024-12-04 |
| CA3196146A1 (en) | 2022-04-28 |
| JP2023546452A (ja) | 2023-11-02 |
| EP4232034A1 (en) | 2023-08-30 |
| AU2021365530A9 (en) | 2024-02-08 |
| WO2022084739A1 (en) | 2022-04-28 |
| IL302174A (en) | 2023-06-01 |
| US20230399317A1 (en) | 2023-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11643429B2 (en) | Compounds and methods for the treatment of ocular disorders | |
| JP7700045B2 (ja) | 眼障害を処置するための化合物および方法 | |
| KR20230110515A (ko) | 눈 장애의 치료를 위한 화합물 및 방법 | |
| AU2020259996B2 (en) | Compounds and methods for the treatment of ocular disorders | |
| CN116670116A (zh) | 用于治疗眼部病症的化合物和方法 | |
| CN116635032A (zh) | 用于治疗眼部病症的化合物和方法 | |
| CN116940570A (zh) | 用于治疗眼部病症的化合物和方法 | |
| HK40100091A (zh) | 用於治疗眼部病症的化合物和方法 | |
| HK40100700A (zh) | 用於治疗眼部病症的化合物和方法 | |
| HK40068671A (en) | Compounds and methods for the treatment of ocular disorders | |
| HK40068817A (en) | Compounds and methods for the treatment of ocular disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40100091 Country of ref document: HK |